Marina Biotech, Inc. (Nasdaq:MRNA) announced the publication of data highlighting the application of their proprietary DiLA2-based delivery technology for systemic administration of siRNAs; this work is described in Molecular Therapy -- a Nature publication. The manuscript, titled "An Amino Acid-based Amphoteric Liposomal Delivery System for Systemic Administration of siRNA" (Adami et al. Molecular Therapy advance online publication 19 April 2011 doi: 10.1038/mt.2011.56; http://www.nature.com/mt/index.html) describes the development of an amphoteric DiLA2 delivery system which enabled efficient knockdown of multiple targets in liver. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the Company's bladder cancer program which utilizes a DiLA2-based delivery technology.
Marina Biotech, Inc. operates as a biotechnology company that focuses on the development and commercialization of therapeutic products based on RNA interference (RNAi). Its pipeline includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome); and two preclinical programs in hepatocellular carcinoma and bladder cancer.
Heska Corp. (Nasdaq:HSKA) reported financial results for its first quarter ended March 31, 2011. Highlights since January 1, 2011 include: 10% growth in year-over-year quarterly revenue, Growth in year-over-year quarterly revenue in both of the Company's operating segments, 34% increase in year-over-year quarterly gross profit, 42.5% Gross Margin - the highest quarterly level in three years, Over $1.5MM in operating income - the second highest quarterly operating income in Heska history, An operating expense increase of less than 1%, Continued net cash balance sheet position, Joe Aperfine employed as Executive Vice President, Sales and Marketing Announcement of a new platform technology agreement.
Heska Corporation engages in the development, manufacture, marketing, sale, and support of veterinary products for canine and feline companion animal health markets in the United States and internationally.
Global Hunter Corp. (BOB.V)
Global Hunter Corp. engages in the acquisition, exploration, and development of mineral properties in Canada and Chile. It primarily explores for gold, copper, and base and precious metals. The company was founded in 1988 and is headquartered in Vancouver, Canada.
Global Hunter's La Corona de Cobre project is over 18,000 hectares of land located in the Coast Range of the Andean Cordillera, Chile, an area often referred to as the Chilean Iron Belt. The property is on the Pan American Highway, 70-kilometres north of the port city La Serena.
The property is located at the southern end of the Atacama Fault Zone, a north-northeast regional feature that stretches for over 1,000 kilometres and hosts several large copper deposits in Chile including Phelps Dodge's Candelaria (400 million tonnes grading 0.95% copper and 0.2% gold) and Anglo-American's Manto Verde (100 million tonnes averaging 0.80% copper) deposits.
Global Hunter Corp. (BOB.V) announced that it has retained the services of Vicarage Capital Limited of London, England to advise it on M&A and corporate finance issues. The key objective is to secure additional financial resources to advance its Corona de Cobre project through any of the following options: negotiating a strategic alliance with a company with significant financial resources; entering into a joint venture, or negotiating a possible merger.
Global Hunter Corp has agreed to pay Vicarage a total of $150,000 CAD over the one-year term of the contract. Vicarage may also be entitled to certain success fees subject to TSX Venture Exchange approval.
Copper is easily stretched, molded, and shaped; is resistant to corrosion; and conducts heat and electricity efficiently. As a result, copper was important to early humans and continues to be a material of choice for a variety of domestic, industrial, and high-technology applications today.
Copper occurs in many forms, but the circumstances that control how, when, and where it is deposited are highly variable. As a result, copper occurs in many different minerals. Chalcopyrite is the most abundant and economically significant of the copper minerals.
For more information about Global Hunter Corp please visit http://www.globalhunter.ca
Targacept, Inc. (Nasdaq:TRGT) reported its financial results for the first quarter ended March 31, 2011. Targacept reported net income of $12.6 million for the first quarter of 2011, compared to net income of $6.8 million for the first quarter of 2010. The improved financial results were principally due to an increase in amounts recognized into revenue from payments previously received from AstraZeneca and GlaxoSmithKline and recorded initially as deferred revenue, partially offset by increased research and development expenses. As of March 31, 2011, cash and investments in marketable securities totaled $230.3 million.
Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system.
Signup for FREE Daily Stock Alerts From http://www.CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.